News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MedWaves, Inc. Announces Receipt of Korean Food and Drug Administration (KFDA) Certification to Import and Sell Its Patented AveCure(TM) Microwave Ablation System and Devices Through Its Distribution Partner in South Korea


8/31/2011 10:43:52 AM

SAN DIEGO, Aug. 31, 2011 /PRNewswire/ -- MedWaves' AveCure Microwave Coagulation-Ablation (MWA) System uses microwave energy to volumetrically coagulate-ablate (destroy) soft-tissue lesions (abnormal structures) safely, effectively, precisely and with repeatability. The system has successfully treated over one-thousand patients worldwide, including lesions in bone, kidney, liver, lung and pancreas. The Company plans to bring its technology to treat lesions in other locations in the body. The Company's technology makes available treatment options for many cancer patients in either early or late stage and helps those who are running out of options.

South Korea, with 48.5 million in population, is an important market for MedWaves. Cancer is the leading cause of death in South Korea, and the Company is pleased to receive KFDA approval to import and sell products. MedWaves is in close coordination with its South Korean distributor-partner in scheduling and conducting clinical evaluations for sales of its AveCure system in key South Korean hospitals.

About AveCure Microwave Coagulation-Ablation System and Devices:

MedWaves' AveCure Microwave Coagulation-Ablation System overcomes the limitations of other microwave and radiofrequency (RF) thermal ablation technologies to destroy lesions safely, effectively, precisely and with repeatability and uniformity. It is the only system approved in the market to provide clinicians with patented fully integrated real-time temperature, both forward and reverse-power feedback to control energy delivery intelligently. The system, which consists of a generator, extension cable set, and an array of single-patient-use microwave-probe devices, enables the surgeons and interventional radiologists to treat soft-tissue lesions, such as tumors, safely and easily, with confidence. This single-patient-use device provides a continuous revenue stream. MedWaves' AveCure Microwave Coagulation-Ablation System has also received USFDA approval for sales in the United States and CE mark for sales in Europe. Other received approval and certification announcements to follow.

About MedWaves, Incorporated

MedWaves, Inc., a United States company based in San Diego, California, develops innovative and proprietary microwave ablation technology for the minimally invasive coagulation-ablation products for soft tissue lesions, such as tumors. The Company's management team has extensive experience in the medical device marketplace. The Company's proprietary technology allows for the development of minimally invasive microwave antenna devices in a wide range of sizes, shapes and flexibility to meet clinicians' requirements in the treatment of lesions in bone, kidney, liver, lung, pancreas and other locations in the body.

Contact Information:

Theodore Ormsby
President/CEO
16760 W Bernardo Drive
San Diego, CA 92127
Tel: 858-946-0015
Mobile: 858-342-3331
Email: tedormsby@avecure.com
Website: http://www.medwaves.com

This press release was issued through eReleases(R). For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.

SOURCE MedWaves, Incorporated


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES